Literature DB >> 8031351

Mycobacterium avium strains resistant to clarithromycin and azithromycin.

L Heifets1, N Mor, J Vanderkolk.   

Abstract

Mycobacterium avium strains susceptible to clarithromycin and azithromycin contain mutants resistant to these macrolides with a frequency of 1.1 x 10(-10) to 1.2 x 10(-6). Cross-resistance between clarithromycin and azithromycin was demonstrated with mutants selected in the laboratory as well as with resistant strains isolated from patients. The susceptibility-resistance patterns of the macrolide-resistant strains with drugs other than macrolides were the same as those of the original susceptible strains. The emergence of clarithromycin resistance in patients was a result of multiplication of the preexisting resistant mutants that survived the elimination of bacteria during the initial period of treatment and was an exclusive cause of the relapse of bacteremia.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8031351      PMCID： PMC192393          DOI： 10.1128/AAC.37.11.2364

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis; results of simultaneous sensitivity tests in liquid and on solid media.

Authors:  D A MITCHISON
Journal:  Thorax       Date:  1950-06       Impact factor: 9.139

2.  Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS.

Authors:  L S Young; L Wiviott; M Wu; P Kolonoski; R Bolan; C B Inderlied
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

3.  MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages.

Authors:  N Mor; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

4.  Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.

Authors:  S P Klemens; M S DeStefano; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

5.  Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals.

Authors:  D M Yajko; P S Nassos; C A Sanders; P C Gonzalez; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

6.  Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium.

Authors:  L B Heifets; P J Lindholm-Levy; R D Comstock
Journal:  Am Rev Respir Dis       Date:  1992-04

7.  Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?

Authors:  N Rastogi; C Frehel; A Ryter; H Ohayon; M Lesourd; H L David
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

Review 8.  The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin.

Authors:  N Bahal; M C Nahata
Journal:  Ann Pharmacother       Date:  1992-01       Impact factor: 3.154

9.  Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system.

Authors:  B A Brown; R J Wallace; G O Onyi
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

10.  Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex.

Authors:  C Truffot-Pernot; B Ji; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191
View more
  31 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

2.  Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection.

Authors:  M A Polis; S C Piscitelli; S Vogel; F G Witebsky; P S Conville; B Petty; J A Kovacs; R T Davey; R E Walker; J Falloon; J A Metcalf; C Craft; H C Lane; H Masur
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice.

Authors:  L E Bermudez; K Nash; M Petrofsky; L S Young; C B Inderlied
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 4.  Antimycobacterial susceptibility testing: present practices and future trends.

Authors:  C B Inderlied
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

Review 5.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 6.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

7.  The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin.

Authors:  C Fréhel; C Offredo; C de Chastellier
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

8.  Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex.

Authors:  Gail L Woods; Natalie Williams-Bouyer; Richard J Wallace; Barbara A Brown-Elliott; Frank G Witebsky; Patricia S Conville; Marianne Plaunt; Geraldine Hall; Priscilla Aralar; Clark Inderlied
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

9.  Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages.

Authors:  C O Onyeji; C H Nightingale; D P Nicolau; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Petrofsky; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.